Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Drug Prescription Patterns and Their Association With Mortality and Hospitalization Duration in Covid-19 Patients: Insights From Big Data Publisher Pubmed



Mehrizi R1 ; Golestani A2 ; Malekpour MR2 ; Karami H1 ; Nasehi MM1, 3 ; Effatpanah M1, 4 ; Ranjbaran H1, 5 ; Shahali Z1 ; Sari AA6 ; Daroudi R6
Authors
Show Affiliations
Authors Affiliations
  1. 1. National Center for Health Insurance Research, Tehran, Iran
  2. 2. Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Pediatric Neurology Research Center, Research Institute for Children Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  4. 4. School of Medicine, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Immunogenetics Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
  6. 6. Department of Health Management, Policy and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Source: Frontiers in Public Health Published:2023


Abstract

Background: Different medication prescription patterns have been associated with varying course of disease and outcomes in COVID-19. Health claims data is a rich source of information on disease treatment and outcomes. We aimed to investigate drug prescription patterns and their association with mortality and hospitalization via insurance data for a relatively long period of the pandemic in Iran. Methods: We retrieved hospitalized patients’ data from Iran Health Insurance Organization (IHIO) spanning 26 months (2020–2022) nationwide. Included were patients with ICD-10 codes U07.1/U07.2 for confirmed/suspected COVID-19. A case was defined as a single hospitalization event for an individual patient. Multiple hospitalizations of a patient within a 30-day interval were aggregated into a single case, while hospitalizations with intervals exceeding 30 days were treated as independent cases. The Anatomical Therapeutic Chemical (ATC) was used for medications classification. The two main study outcomes were general and intensive care unit (ICU) hospitalization periods and mortality. Besides, various demographic and clinical associate factors were analyzed to derive the associations with medication prescription patterns and study outcomes using accelerated failure time (AFT) and logistic regression models. Results: During the 26 months of the study period, 1,113,678 admissions with COVID-19 diagnosis at hospitals working in company with IHIO were recorded. 917,198 cases were detected from the database, among which 51.91% were females and 48.09% were males. Among the main groups of medications, antithrombotics (55.84% [95% CI: 55.74–55.94]), corticosteroids (54.14% [54.04–54.24]), and antibiotics (42.22% [42.12–42.32]) were the top used medications among cases with COVID-19. Investigation of the duration of hospitalization based on main medication groups showed antithrombotics (adjusted median ratio = 0.94 [0.94–0.95]) were significantly associated with shorter periods of overall hospitalization. Also, antithrombotics (adjusted odds ratio = 0.74 [95%CI, 0.73–0.76]), corticosteroids (0.97 [0.95–0.99]), antivirals (0.82 [0.80–0.83]), and ACE inhibitor/ARB (0.79 [0.77–0.80]) were significantly associated with lower mortality. Conclusion: Over 2 years of investigation, antithrombotics, corticosteroids, and antibiotics were the top medications for hospitalized patients with COVID-19. Trends in medication prescription varied based on various factors across the country. Medication prescriptions could potentially significantly impact the trends of mortality and hospitalization during epidemics, thereby affecting both health and economic burdens. Copyright © 2023 Mehrizi, Golestani, Malekpour, Karami, Nasehi, Effatpanah, Ranjbaran, Shahali, Sari and Daroudi.
Other Related Docs
10. The Effect of Macroeconomic Indicators on Health-Care Expenditure in Iran, Journal of Education and Health Promotion (2019)
11. Therapeutic Strategies for Covid-19 Patients: An Update, Infectious Disorders - Drug Targets (2022)
19. The Kidney Transplantation Program in Iran, Philosophy and Medicine (2023)
20. Studying the Impoverishing Effects of Procuring Medicines: A National Study, BMC International Health and Human Rights (2019)
23. A Review of Antibiotic Efficacy in Covid-19 Control, Journal of Immunology Research (2023)
26. Future Financing Scenarios for Iran's Healthcare System, Archives of Iranian Medicine (2022)
29. Health Sector Evolution Plan in Iran; Equity and Sustainability Concerns, International Journal of Health Policy and Management (2015)
31. Decomposition of Health Inequality Determinants in Shiraz, South-West Iran, Journal of Research in Health Sciences (2015)
33. Therapeutic Potentials and Candidates for Covid-19, Iranian Journal of Science (2023)
35. Remdesivir: Treatment of Covid-19 in Special Populations, Naunyn-Schmiedeberg's Archives of Pharmacology (2024)
36. Researchable Clinical Problems From the Viewpoint of Healthcare Providers: A Qualitative Study, Journal of Mazandaran University of Medical Sciences (2019)
38. History of Health Technology Assessment in Iran, International Journal of Technology Assessment in Health Care (2020)
40. The Projection of Iran’S Healthcare Expenditures by 2030: Evidence of a Time-Series Analysis, International Journal of Health Policy and Management (2022)
42. Insecure Employment Contracts During the Covid-19 Pandemic and the Need for Participation in Policy Making, International Journal of Environmental Research and Public Health (2021)
48. Universal Health Coverage in Iran: Where We Stand and How We Can Move Forward, Medical Journal of the Islamic Republic of Iran (2019)
49. Policy Options to Reduce Fragmentation in the Pooling of Health Insurance Funds in Iran, International Journal of Health Policy and Management (2016)